Trastuzumab Deruxtecan Sustains Survival Benefits in HER2-Low Metastatic Breast Cancer
October 21st 2023Treatment with fam-trastuzumab deruxtecan-nxki led to sustained improvements in overall survival and progression-free survival vs physician’s choice of treatment in patients with previously treated HER2-low metastatic breast cancer, irrespective of hormone receptor status.
Read More
Senaparib Maintenance Generates PFS Benefit in Advanced Ovarian Cancer
October 20th 2023Maintenance therapy consisting of single-agent senaparib reduced the risk of progression or death vs placebo in patients with newly diagnosed advanced ovarian cancer, irrespective of BRCA mutation status.
Read More
Teclistamab Delivers Comparable Efficacy Between Real-World and MajesTEC-1 Myeloma Populations
September 29th 2023Treatment with teclistamab-cqyv in real-world patients with relapsed/refractory multiple myeloma elicited similar efficacy results and a comparable safety profile to findings from the phase 1/2 Majes-TEC-1 trial.
Read More
Daratumumab Plus Ixazomib and Dexamethasone Produces Significant Responses in R/R Multiple Myeloma
June 9th 2023The combination of daratumumab, ixazomib, and dexamethasone produced rapid and encouraging responses rates following lenalidomide–based therapy in patients with relapsed/refractory multiple myeloma, according to findings from the final analysis of the phase 2 DARIA trial.
Read More
HER3-DXd Elicits Responses and Safety in Heavily Pretreated ER+ Breast Cancer and TNBC
June 5th 2023Patritumab deruxtecan displayed manageable safety and produced responses in heavily pretreated patients with estrogen receptor–positive or triple-negative metastatic breast cancer with varying levels of HER3 expression, according to data from a phase 2 study presented at the 2023 ASCO Annual Meeting.
Read More
Olaparib Plus Selumetinib Produces Clinical Benefit in RAS-Mutated Ovarian and Endometrial Cancer
March 27th 2023The recommended phase 2 dose of olaparib plus selumetinib generated a clinical benefit in patients with endometrial or ovarian cancer harboring RAS mutations, according to findings from the dose-expansion portion of the phase 1b SOLAR trial.
Read More
Nivolumab Plus Salvage Immunotherapy Leads to High TFS Rates in Advanced RCC
February 21st 2023Nivolumab monotherapy, plus salvage nivolumab plus ipilimumab for progressive disease, resulted in high treatment-free survival rates in patients with previously untreated advanced clear cell renal cell carcinoma.
Read More
HER2-Low Classification Is Associated With Distinct Clinical Features in Advanced Gastric Cancer
January 19th 2023Clinicopathological features of HER2-low advanced gastric cancer were distinct and distinguishable from those of HER2-positive or -negative disease, according to retrospective findings from a single-institution study that were presented at the 2022 Gastrointestinal Cancers Symposium.
Read More
Rituximab/Lenalidomide Shows Sustained PFS Benefit in Indolent Non-Hodgkin Lymphoma
December 10th 2022The combination of rituximab and lenalidomide maintained improved progression-free survival compared with rituximab alone in patients with relapsed/refractory indolent non-Hodgkin lymphoma, according to 5-year findings from the phase 3 AUGMENT trial.
Read More
Capivasertib Plus Fulvestrant Elicits PFS Benefit in HR+/HER2- Advanced Breast Cancer
December 8th 2022The combination of capivasertib plus fulvestrant significantly improved progression-free survival vs fulvestrant alone in patients with hormone receptor–positive/HER2-negative advanced breast cancer, including those with AKT pathway–altered tumors.
Read More
Pembrolizumab/Olaparib Combo Fails to Improve rPFS, OS Vs Novel Hormonal Agents in mCRPC
September 12th 2022The combination of pembrolizumab and olaparib did not significantly improve radiographic progression-free survival and overall survival compared with novel hormonal agents in patients with molecularly unselected, previously treated metastatic castration-resistant prostate cancer.
Read More